TWI914404B - 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 - Google Patents
利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法Info
- Publication number
- TWI914404B TWI914404B TW110134367A TW110134367A TWI914404B TW I914404 B TWI914404 B TW I914404B TW 110134367 A TW110134367 A TW 110134367A TW 110134367 A TW110134367 A TW 110134367A TW I914404 B TWI914404 B TW I914404B
- Authority
- TW
- Taiwan
- Prior art keywords
- inhibitors
- week
- compound
- cancer
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078833P | 2020-09-15 | 2020-09-15 | |
| US63/078,833 | 2020-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202227059A TW202227059A (zh) | 2022-07-16 |
| TWI914404B true TWI914404B (zh) | 2026-02-11 |
Family
ID=80776688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110134367A TWI914404B (zh) | 2020-09-15 | 2021-09-15 | 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230338342A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4213841A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541430A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230067646A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021344091A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI914404B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022059691A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019107386A1 (ja) | 2017-11-29 | 2019-06-06 | 大鵬薬品工業株式会社 | 抗腫瘍剤 |
| US20200157066A1 (en) | 2016-05-31 | 2020-05-21 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide Compound or Salt Thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011121453A2 (en) * | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
-
2021
- 2021-09-15 WO PCT/JP2021/033854 patent/WO2022059691A1/en not_active Ceased
- 2021-09-15 JP JP2023516473A patent/JP2023541430A/ja active Pending
- 2021-09-15 TW TW110134367A patent/TWI914404B/zh active
- 2021-09-15 US US18/044,978 patent/US20230338342A1/en active Pending
- 2021-09-15 AU AU2021344091A patent/AU2021344091A1/en active Pending
- 2021-09-15 EP EP21869377.8A patent/EP4213841A4/en not_active Withdrawn
- 2021-09-15 KR KR1020237012412A patent/KR20230067646A/ko active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200157066A1 (en) | 2016-05-31 | 2020-05-21 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide Compound or Salt Thereof |
| WO2019107386A1 (ja) | 2017-11-29 | 2019-06-06 | 大鵬薬品工業株式会社 | 抗腫瘍剤 |
Non-Patent Citations (3)
| Title |
|---|
| 期刊 John Murren, et al "Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors." Clin Cancer Res 9(11) 2003 Sep 15 4092-4100 |
| 期刊 Kelli L Goss, et al "Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma." Oncotarget 7(39) 2016 Sep 27 63003-63019 |
| 期刊 加藤裕久 "がん薬物療法におけるレジメン管理" Japanese Journal of Drug Informatics 2010, Vol.11, No.4 pp.217-222 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230067646A (ko) | 2023-05-16 |
| AU2021344091A9 (en) | 2024-08-08 |
| JP2023541430A (ja) | 2023-10-02 |
| EP4213841A1 (en) | 2023-07-26 |
| US20230338342A1 (en) | 2023-10-26 |
| TW202227059A (zh) | 2022-07-16 |
| WO2022059691A1 (en) | 2022-03-24 |
| AU2021344091A1 (en) | 2023-05-25 |
| EP4213841A4 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4213842B1 (en) | Ribonucleotide reductase inhibitor for use in a method of treating tumors | |
| US20230338342A1 (en) | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor | |
| CN113038953B (zh) | 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法 | |
| CN121487738A (zh) | 诱导ras gtp水解的组合物和其用途 | |
| KR20250169290A (ko) | Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법 | |
| US20250049810A1 (en) | Methods of treating a ras protein-related disease or disorder | |
| EP4704850A1 (en) | Combination therapy for a ras related disease or disorder | |
| TW202502351A (zh) | 治療ras相關疾病或病症之方法 | |
| WO2025255438A1 (en) | Methods of treating a ras protein-related disease or disorder | |
| RU2859365C2 (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| RU2848459C1 (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| TW202329934A (zh) | 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法 | |
| US20240408100A1 (en) | Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway | |
| WO2026015825A1 (en) | Use of ras inhibitor for treating pancreatic cancer | |
| HK40129790A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| WO2026015801A1 (en) | Methods of treating a ras related disease or disorder | |
| HK40055650A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| HK40051935A (en) | Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| HK40051935B (en) | Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |